Ownership of Avalo Therapeutics (AVTX) includes prominent institutional asset management firms, specialized healthcare funds, and mutual fund index providers. Major institutional stakeholders holding significant blocks of common stock comprise professional investment houses and exchange-traded fund managers that provide public market liquidity and capital support to advance the company's clinical-stage therapeutic pipeline.